Bayer's Advertising for Contraceptive Yaz Was "Misleading"

Last Updated Feb 10, 2009 8:40 PM EST

Bayer will run a $20 million corrective ad campaign for its contraceptive brand Yaz to settle a case where it was accused of deceptive advertising.

The news cements Bayer's reputation as the most ethically challenged pharma company in the business -- it is only the latest in an increasingly long string of citations and settlements in which Bayer has been accused of deceptive marketing. (See list below.) The previous accusations cover both Rx and OTC drugs, diet supplements and veterinary treatments. Reuters:
The latest judgment, filed in Massachusetts' Suffolk Superior Court, resolves allegations that Bayer's 2008 marketing of Yaz violated the terms of the 2007 agreement by not disclosing the uses for which Yaz has been approved by the U.S. Food and Drug Administration.

The 2007 agreement involved allegations of deceptive advertising, including a failure to disclose the safety risks in Bayer's marketing of its cholesterol drug Baycol, which was withdrawn in 2001.
Bayer must now submit all its Yaz ads to the FDA for prior approval. Bayer had just invested a bunch of cash in an endorsement deal with The Hills star Lo Bosworth. Bayer was caught by the Boston AG claiming Yaz treated PMS when the FDA has never approved it for that use. It's not the first time Bayer has been found advertising unapproved uses of drugs. In October 2008, the company was slammed for selling aspirin for unapproved uses.

Comments

Market Data

Market News

Stock Watchlist